<DOC>
	<DOC>NCT01224834</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of several doses of ragweed pollen allergen extract administered as sublingual tablets in subjects with allergic rhinitis to ragweed.</brief_summary>
	<brief_title>Safety and Tolerability Study of Ragweed SLIT Tablets</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<criteria>written consent male or female subjects from 18 yo 60 years old and in general good health for women of child bearing potential: negative urine pregnancy test and use of medically effective contraceptive method symptoms of ragweed pollen induced allergic rhinitis for at least the last 2 years sensitization to ragweed pollen as demonstrated with positive skin prick test to ragweed pollen and specific IgE level (ragweed pollen) &gt; 0.70 kU/l at screening FEV1 at least of 80% of predicted value at screening past or current disease which, as judged by the investigator, may affect the outcome of this study history of lifethreatening asthma asthma requiring daily treatment (whatever the pharmaceutical class) pregnant or lactating women subjects who previously received desensitisation treatment to ragweed pollen and/or other Asteraceae or who plan to start desensitisation treatment during this study symptoms during the treatment phase due to a sensitivity to a second allergen subjects treated with ongoing immunotherapy with another allergen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Ragweed, allergy, sublingual immunotherapy</keyword>
</DOC>